Skip to main content

Biomarkers for Lung Cancer: What Your Test Results Mean

Which Biomarkers Matter for Lung Cancer

A lung cancer biomarker is a measurable change in a tumor's genes or proteins that can point toward a specific treatment. The label works like a lock face: some medicines were machined to fit one exact shape, and biomarker testing is how the lab reads which shape a tumor carries.

For non-small cell lung cancer, the FDA list of authorized companion diagnostics names tests for EGFR exon 19 deletions and exon 21 L858R substitutions, EGFR T790M, ALK gene rearrangements and KRAS G12C. Each device is indicated for a specific therapeutic product or products, and some are indicated for a specific group of oncology therapeutic products, so a lung cancer can be read on its own biology rather than treated as identical to the next. That link between test and medicine is why a result carries weight, because it can decide whether a particular drug is on the table at all.

EGFR shows how much a single label can change a plan. In a 2010 review table, EGFR-mutated NSCLC was listed at about 10% of NSCLC cases, and the EGFR tyrosine-kinase inhibitors erlotinib and gefitinib were listed with response rates around 75%, compared with about 30% for conventional chemotherapy (2010 review of ALK inhibition in NSCLC).

A broad panel may also name BRAF V600E, MET exon 14 skipping, RET fusions, NTRK fusions and HER2 mutations. Whether they appear on your report depends on the panel your laboratory runs, which in turn depends on the cancer type, the stage, prior treatment and the lab's menu. Small cell lung cancer follows a different path, and this table covers non-small cell disease only.

Two reports can look similar and still say different things. A biomarker missing from the list may reflect what the panel covered, how much tissue the lab received, or what the tumor carries, and your oncology team can tell you which applies. Treat this table as a map to review with that team before any decision.

BiomarkerWhat it meansMatched treatment type
EGFR mutationsChanges in the EGFR gene that can drive tumor growthEGFR tyrosine-kinase inhibitors
ALK rearrangementsThe ALK gene joined to another geneALK inhibitors
ROS1 rearrangementsThe ROS1 gene joined to another geneROS1-targeted therapy
KRAS G12CA specific change in the KRAS geneKRAS G12C inhibitors
PD-L1 expressionThe amount of PD-L1 protein on tumor cellsImmunotherapy selection

This is not clinical evidence and not medical advice. It does not replace your care team. Discuss anything here with your clinician before you act on it. Product questions are on the FAQ.

Made by Triangle.

What does it mean when a lung cancer biomarker report says that no change was detected? It can mean three different things, and only one of them is a true negative. A biomarker is a measurable change in a tumor's genes or proteins that may match a specific drug or an immunotherapy, and a result is only as complete as the sample and the panel behind it.

This guide explains which biomarkers matter in lung cancer, how testing runs from biopsy to report, how to tell a true negative from an incomplete one, and which questions to bring to the oncology team. Every testing and treatment decision stays with that team.

How Biomarker Testing Works, Step by Step

A biomarker report looks simple when it arrives. Behind it sits a short chain of steps, and every step can lose information if nobody plans for it.

  1. The doctor orders tissue testing. Most testing starts with a biopsy or a surgical sample taken before treatment begins, so the tissue is collected in a way that preserves enough material for molecular analysis. The American Lung Association's biomarker testing quiz says the best time to talk about testing is before the biopsy, for exactly that reason. The common gap is a biopsy planned only for diagnosis, with no molecular request attached.
  2. The lab checks the sample. A pathologist confirms how much tumor sits in the block and whether that's enough for the panel that was ordered. The common gap is a thin needle sample made mostly of normal tissue, which caps what can be sequenced.
  3. The lab runs a broad panel. Next-generation sequencing reads many genes from one specimen. When possible, a sequencing panel that covers EGFR, ALK and ROS1 along with other targetable genes is encouraged, because it can detect mutations, gene copy changes and rearrangements together, even from small amounts of input (overview of biomarker testing in advanced NSCLC). The common gap is single-gene testing that consumes the sample one gene at a time.
  4. PD-L1 is stained separately. PD-L1 is a protein, and standard DNA sequencing doesn't measure it, so it's read by immunohistochemistry on its own slide. The common gap is assuming a DNA panel already answered the PD-L1 question.
  5. A blood test may be added. When tissue is limited or a patient has relapsed, plasma circulating tumor DNA can give a faster answer or fill a hole. The common gap is treating a plasma result as complete on its own.
  6. The lab issues the report. A molecular or pathology report lists each gene tested and its result, usually with a note on the method used. The common gap is a one-page summary that names findings but never says which genes went untested.
  7. The oncology team interprets it. The team reads the report against the scan, the stage and prior treatment, and may order retesting when something is unclear or incomplete. The common gap is a report filed away without asking whether more testing would change the plan.

Ask for the full report, not the summary page. The gene list and the limitations section are where an incomplete workup becomes visible.

What a complete report should show. Every gene tested with its result, the sample type and where it came from, the PD-L1 result if it was ordered, the platform or assay name, and any limitations the laboratory states. If one of those is missing, that's a question for the team.

Choosing the Right Sample

A tissue sample lets the lab read the tumor directly, across many genes at once. A blood draw reads only the tumor DNA that has shed into the plasma, so it can miss changes that a tissue test would find. Both are real tests. They answer different questions, and a complete workup sometimes uses each one.

The blood-based approach is called a liquid biopsy. The FDA documentation for the Guardant360 CDx plasma test describes a test that uses circulating cell-free DNA from plasma collected from peripheral whole blood and is intended to identify some patients with NSCLC who may benefit from targeted therapies. The same document says NSCLC patients who are "negative for the biomarkers listed in Table 1 should be reflexed to tissue biopsy testing" for those biomarkers, if feasible, which is why a negative plasma result does not settle the question on its own.

The choice can depend on how much tissue is available, the suspected mutation, the cancer's stage, and the test's approved use. A small biopsy that yielded little tumor may push the team toward plasma first, while a surgical specimen usually supports the broadest panel. Timing matters too, since a blood draw can sometimes be arranged faster than a repeat biopsy. The oncology team weighs all of this against how quickly an answer is needed.

Three questions keep the sample decision clear:

  • Which sample did the lab test? Tissue and plasma answer different questions, and the report should name the specimen type.
  • Does a negative result need confirmation? Ask whether tissue is still available or whether a repeat sample is planned.
  • How does the lab state its limits? Look for the limitations section rather than reading the findings page alone.

The specimen line on the report tells you which question was asked.

FeatureTissue biopsyPlasma blood test
SamplePiece of tumor from a biopsy or surgeryBlood draw
Tests usually runBroad NGS panels plus PD-L1 stainingTargeted panels, often including EGFR
Best whenEnough tumor is available for a full workupTissue is limited or more testing is needed
Negative resultStrong guide, but check which genes the panel coveredDoes not rule out a biomarker in the tumor; confirmation may be needed
What Negative and Incomplete Results Mean in Practice

A negative biomarker result does not mean the cancer has no targetable change. Reading it that way can close a conversation that should stay open. A negative line describes what one test did or didn't find in one sample, and the summary page may not show the difference between a true negative and a test that never had a fair chance.

Three situations can look identical on a findings page and mean very different things. No change was detected in an adequate sample. The sample was too small or degraded to test properly. The panel didn't include the relevant gene. A fourth case is easy to file with them but is not a negative at all: a change was found, but no approved medicine exists in that setting. That is a positive finding, and it can still matter for a trial. A negative blood result adds one more layer, because the amount of tumor DNA in the blood is proportional to the overall burden of disease (overview of biomarker testing in advanced NSCLC), and FDA labeling for one plasma test says a negative result from a plasma specimen does not assure that the tumor is negative for genomic findings, which is why a plasma result doesn't always replace tissue testing (FDA labeling for the Guardant360 CDx plasma test).

Biomarker data can be missing even in large research datasets. Of the 64,434 cases in the NSCLC database of an International Association for the Study of Lung Cancer committee, diagnosed from 2010 to 2019 across Asia, Australia, North America and Europe, 6,611 (10%) were Electronic Data Capture (EDC) cases, and of these, 2,068 (31%) had biomarker data (IASLC molecular dataset findings).

A negative line answers one question about one sample. It rarely answers the whole question about the tumor.

Possible meaningWhat to askExample
No change detectedWas the sample adequate and did the panel cover the gene?Tissue panel shows no EGFR change
Sample too small or degradedIs retesting or a repeat sample needed?Tissue too small for full panel
Gene not on the panelWhich genes were tested?Relevant gene missing from report
Not a negative: change found, no approved medicine in this settingIs there a matched treatment, and in what setting?Gene change with no approved drug at this stage
Sorting a Report in Four Steps
  1. Check the sample type. Tissue and plasma carry different limits, and the report should say which one was tested.
  2. Check which genes were tested. Compare that list against the biomarkers linked to lung cancer treatment, not against the word "negative."
  3. Check whether any finding has a matched treatment. A change without an approved drug today can still matter for a trial.
  4. Check whether the negative is marked as limited. A limitations note is the laboratory telling you what the assay couldn't see.

Reading the pathology report is a separate skill, and a walkthrough of how to read a pathology report covers the sections worth checking before the next appointment. Before treating any negative as final, ask what it covers and confirm every decision with the care team.

Questions to Bring to Your Oncology Team

Appointments are short and reports are dense. A written list keeps the important questions from being squeezed out at the end.

  1. Which genes were tested, and did the panel include the biomarkers linked to lung cancer treatment? A missing gene leaves a treatment option unanswered even when every result on the page looks normal.
  2. Was the sample tissue, blood or both, and was there enough tumor to test? Sample failure from inadequate tumor tissue is common in practice (overview of biomarker testing in advanced NSCLC).
  3. Was PD-L1 tested, and what was the result? It's measured separately from gene testing and informs immunotherapy discussions.
  4. Does any finding have a matched treatment, and in what setting? A change with an approved drug in one stage or line of treatment may not have one in yours.
  5. Does a negative or unclear result need confirmation, retesting or a repeat sample? This is the question that turns a dead end into a next step.
  6. What limitations does the lab state on the report? The limitations section names what the assay can't detect.
  7. Would a clinical trial match the findings, and what are its requirements? Trials accept specific alterations and specific prior treatments, so the requirements decide eligibility.
  8. When should biomarker status be reviewed again as the disease changes? Biomarkers in a cancer can change over time, and the team may revisit testing at relapse or progression.

Write the answers down in a notebook or a shared file, so the patient and the caregiver can review them together later. Memory is unreliable in a consultation room, and a written answer can be reread at home.

A wider set of questions to ask your oncologist covers the treatment conversation around the report. Bring this list as support for that discussion, not as a replacement for it, because the oncology team decides on testing and treatment.

Confirm Your Next Step With Your Care Team

Gather the documents first, then the questions.

  1. Collect the reports. The pathology report, the molecular or biomarker report, recent imaging reports, and any blood results that mention tumor DNA or biomarkers.
  2. Label each one. Write the date, the sample type and the laboratory name on every report, because the team compares results over time and needs to know when and where each came from.
  3. Ask the team what it needs. Which report they want first, whether imaging files on disc are required, and whether any result should be confirmed before the next visit.
  4. Prepare two or three questions. A short list gets answered; a long one gets deferred.

A service such as Triangle can help you get the file into one place. Triangle reads your records with you and helps you prepare questions, so you can walk into the next visit with questions that came from your records, not from a search bar. It does not diagnose, treat, or prescribe, and it never replaces your care team.

Bring the papers, not just the diagnosis.

If a trial enters the conversation, read the eligibility section closely. A listing such as treatment for advanced non-small cell lung cancer with an actionable alteration is worth reading alongside the full protocol, because eligibility turns on details rather than on the headline.

The care team makes every decision about testing and treatment. This guide is educational and isn't medical advice.

Can biomarker status change over time?

The biomarkers in a cancer can change over time, and a test only captures a snapshot at one point in time, so the team may discuss retesting, for example if the cancer comes back after treatment. Retesting decisions stay with the care team.

Does a biomarker mean I will receive a specific drug?

No. A biomarker is one factor among several. Even when a test finds a biomarker that matches an available treatment, the therapy may not work, because other features of the cancer or the body sometimes affect how well a treatment works, and the care team discusses the results to decide on a treatment.

Is PD-L1 the same as a gene change?

No. PD-L1 is a protein measured by a separate stain, and it informs immunotherapy discussions rather than matching a gene-targeted drug.

Should I ask for the full report?

Yes. The lab report lists the biomarkers in the cancer cells and whether any treatments might work, and a summary page may not show which genes were tested or any limitations.

Confirm every testing and treatment decision with your oncology team.

See how Triangle helps you understand your file →

Sources

For you, or someone you love

Ask this about your own records.

Triangle brings your medical records, genetic results and wearables into one place that you control, with your records organised by condition. Ask about your own file in plain language, and walk into every appointment knowing what to ask.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks, next to your genetic results and wearables. Add scans and anything on paper.

  • Read in plain words

    Reports explained as they come in, organised by condition, with lab values you can follow over time.

  • Ready for every appointment

    Ask about your own file, and walk in knowing what to ask your doctors.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.